NCT02947347 2026-03-17Study of Ibrutinib and Rituximab in Treatment Naïve Follicular LymphomaPharmacyclics LLC.Phase 3 Completed445 enrolled 18 charts
NCT05431179 2023-04-21A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell LymphomaOncternal Therapeutics, IncPhase 3 Withdrawn
NCT02703272 2022-12-02A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin LymphomaJanssen Research & Development, LLCPhase 3 Terminated72 enrolled 36 charts
NCT02165397 2021-03-03Ibrutinib With Rituximab in Adults With Waldenström's MacroglobulinemiaPharmacyclics LLC.Phase 3 Completed181 enrolled 20 charts